CTOs on the Move

Day One Biopharmaceuticals

www.dayonebio.com

 
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.dayonebio.com
  • 395 Oyster Point Blvd Suite 217
    South San Francisco, CA USA 94080
  • Phone: 650.770.9034

Executives

Name Title Contact Details

Funding

Day One Biopharmaceuticals raised $60M on 05/21/2020
Day One Biopharmaceuticals raised $130M on 02/10/2021

Similar Companies

American Society of Dermatopathology

American Society of Dermatopathology is a Northbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akaza Research

Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Ag-Products

Horizon Ag-Products, LP is a science and research-driven producer of innovative plant health solutions. We specialize in naturally-derived plant health products for the global agricultural market. Horizon Ag-Products is not a fertilizer company. We mak...

Biocomputing Platforms

Biocomputing Platforms is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PhaseBio

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our elastin-like polypeptide technology, which also serves as the engine for our preclinical pipeline. Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance. PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical studies in pulmonary arterial hypertension (PAH) and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction. We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.